title: From genome to drugs: where do we stand?
authors.forename: Charlie
authors.initials: C
authors.lastname: Schmidt
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000494:pharmacology*; D001549:Benzamides; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D019008:Drug Resistance, Neoplasm; D015894:Genome, Human; D023281:Genomics / Q000639:trends*; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000494:pharmacology; D058990:Molecular Targeted Therapy / Q000639:trends*; D009154:Mutation; D009363:Neoplasm Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009965:Orphan Drug Production / Q000191:economics; D010879:Piperazines / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000494:pharmacology; D048493:Proto-Oncogene Proteins B-raf / Q000187:drug effects / Q000235:genetics; D011743:Pyrimidines / Q000494:pharmacology; D035583:Rare Diseases / Q000188:drug therapy / Q000235:genetics; D013449:Sulfonamides / Q000494:pharmacology; D014481:United States; D014486:United States Food and Drug Administration; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D009363:Neoplasm Proteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000077484:Vemurafenib; D000068877:Imatinib Mesylate; D048493:Proto-Oncogene Proteins B-raf